Patient-based and clinician-based support for the remission criteria in schizophrenia

International Clinical Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 51-55

  Docherty, John P ^a   Bossie, Cynthia A ^b   Lachaux, Bernard ^c   Bouhours, Philippe ^d   Zhu, Young ^e   Lasser, Robert ^f   Gharabawi, Georges M ^b  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Centre Hospitalier Paul Guiraud   (France)

^d Janssen Cilag   (France)

^e Quantitative Methodology   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Long acting risperidone; Positive and Negative Syndrome Scale; Remission; Schizoaffective disorder; Schizophrenia

Indexed keywords

RISPERIDONE;

ARTICLE; ATTITUDE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH STATUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL HEALTH; PRIORITY JOURNAL; PROBABILITY; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; VALIDITY;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PATIENTS; PHYSICIANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845677728     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224791.06159.88     Document Type: Article

References (11)

1. American Psychiatric Association (1994). DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, District of Columbia: American Psychiatric Press.
2. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449.
3. Fleischhacker WW, Eerdekens M, Karcher K, Remmington G, Llorca PM, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
4. Guy W (1976). ECDEU assessment manual for psychopharmacology, revised. Rockville, Maryland: US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration; NIMH Psychopharmacology Research Branch; Division of Extramural Research Programs; pp. 218-222. DHEW Publ No ADM 76-338.
5. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
6. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
7. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA (2004). Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 83:263-275.
8. Lasser RA, Bossie CA, Gharabawi GM, Kane JM (2005). Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77:215-227.
9. Sethuraman G, Taylor CC, Enerson M, Dunayevich E (2005). A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res 79:337-340.
10. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. (2006). Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113(2):91-95.
11. Ware JE Jr, Sherbourne CD (1992). The MOS 36-item short form health survey (SF-36), I: conceptual framework and item selection. Med Care 30:473-483.